Valvular Heart Disease Stenosis and RegurgitationNCT07099417
Screening of Valvular Heart Disease Using Single-channel Electrocardiogram
An observational study of Valvular Heart Disease Stenosis and Regurgitation and Valvular Heart Disease, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.
Trial summary
It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 1000 patients over 18 years old in the training sample and 200 patients over 18 years old in the test sample (the total number of patients is at least 1200 people). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Valvular Heart Disease Stenosis and Regurgitation, Valvular Heart Disease
- How many people
- 1,200 participants
- Where
- 1 siteRussia
- Study dates
- 1 Jan 2025to 31 Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All patients over 18 years old
Who may be able to join
- The presence of written informed consent of the patient to participate in the study
- Age from 18 years
- Outpatient treatment and / or hospitalization in a research center
Who cannot join
- Reluctance of the patient to participate in the study
- Poor quality ECG recording on a single-channel ECG monitor
- Poor visualization of the heart during echocardiographic study
- Acute psychotic reactions that arose during research
- An exacerbation of chronic diseases requiring treatment tactics for the patient and preventing his further participation in the study.
- Non-inclusion criteria:
Show all 11Show fewer
- Poor quality ECG recording on a single-channel ECG monitor
- Conditions that can impair ECG recording quality (Parkinson's disease, essential tremor)
- Mental illness
- Patients with a pacemaker installed
- Patients with prosthetic valves
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, 119048
About this study
Official title: Screening of Valvular Heart Disease Using Single-channel Electrocardiogram Analyzed With Machine Learning Models
It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 1000 patients over 18 years old in the training sample and 200 patients over 18 years old in the test sample (the total number of patients is at least 1200 people).
All patients will undergo an echocardiography examination with a comprehensive analysis of the function of the valves and other structures of the heart according to current recommendations by two independent experts.
Read more
Registration of electrocardiogram will be performed immediately after echocardiography using a single lead ECG monitor (in I standard lead) for 1 minutes.
The obtained data will be stored in the remote monitoring center of Sechenov University without being linked to the personal data of patients.
A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.
The result of this study will be the identification of ECG parameters that will correlate with valvular heart disease.
Read the detailed description
The aim of the study: to create and evaluate the diagnostic efficiency of a method for screening valvular heart disease based on data obtained from the analysis of a single-channel electrocardiogram.
It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 1000 patients over 18 years old in the training sample and 200 patients over 18 years old in the test sample (the total number of patients is at least 1200 people).
All subjects will undergo echocardiography with a comprehensive analysis of the function of the valves and other structures of the heart according to current recommendations by two independent experts.
Immediately after echocardiography, ECG registration will be performed in lead I for 1 minute with subsequent spectral analysis of the obtained data, which will be stored in the remote monitoring center of Sechenov University without reference to the personal data of the patients.
Single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Supervision on February 15, 2019. RZN No. 2019/8124.
If pathology is detected during echocardiography or ECG, the patient will be given a recommendation on the need to consult a cardiologist.
The patient's personal data (last name, first name, patronymic, date of birth, contact information) will not be transferred or taken into account. Each patient is assigned an individual number that is not associated with his/her personal data.
Then a spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform, the principles of which are based on the Fourier transform.
The analysis involves the evaluation of the following parameters (the parameters listed below will be calculated as the median of the tact-cycle):
- TpTe - time from peak to end of the T-wave
- VAT - time from the beginning of the QRS to the R-peak
- QTc - corrected QT interval.
- QT / TQ - the ratio of QT length to TQ length (from the end of T to the beginning of the QRS of the next complex).
- QRS_E - the total energy of the QRS wave based on the wavelet transform
- T_E - T-wave total energy based on wavelet transform
- TP_E- energy of the main tooth of the T-wave based on the wavelet transform
- BETA, BETA_S - T-wave asymmetry coefficients (simple and smooth versions)
- BAD_T - flag of T-wave quality (whether expressed in the current lead
- QRS_D1_ons - energy of the leading edge of the R-wave (based on the "first derivative" wavelet transform)
- QRS_D1_offs - energy of the trailing edge of the R-wave (based on the "first derivative" wavelet transform)
- QRS_D2 - peak energy of the R-wave (based on the "second derivative" wavelet transform)
- QRS_Ei (i = 1,2,3,4) - QRS-wave energy in 4 frequency ranges (2-4-8-16-32 Hz) based on wavelet transform
- T_Ei (i = 1,2,3,4) - T-wave energy in 4 frequency ranges (2-4-6-8-10 Hz) based on wavelet transform
- HFQRS - the amplitude of the RF components of the QRS wave
Additionally used parameters:
- TpTe, VAT, QTc - are duplicated to control the correctness of the record processing (the value of the UCC should be approximately equal to the median of the tick-by-bar).
- QRSw - QRS width.
- RA, SA, TA - the amplitudes of the R, S, T-waves, respectively, are used to normalize the parameters listed above.
Statistical analysis and modeling will be performed using Python V3.8.8 and R V.4.0 programming languages, as well as SPSS v.17 software. The correlation between various combinations of time, amplitude and frequency parameters of ECG and the presence and degree of valvular heart defects will be analyzed. Certain parameters will be included in various multivariate analysis models: Lasso regression, Random Forest, Multilayer Perceptron, Support Vector Machine and Decision Tree. The model with the highest diagnostic accuracy will be selected, on which the algorithm will be tested.
The result of this study will be the development and testing of an algorithm for identifying valvular heart disease based on the analysis of single-channel ECG parameters. With the subsequent possibility of determining the degree of valvular heart disease.
Study endpoints:
- parameters of single-channel ECG that have a reliable correlation with the presence of valvular heart defects;
- sensitivity, specificity and diagnostic accuracy of multivariate models for analyzing single-channel electrocardiogram data;
- diagnostic accuracy of the algorithm when tested on a test sample of patients.
- Being tested
- No intervention (observational study)
- Keywords
- valvular heart disease, Screening, single-channel electrocardiogram, machine learning models
- Medical subject headings
- Gastroesophageal Reflux, Heart Valve Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention (observational study)Diagnostic test
No intervention (observational study)
| Study group | Role | What they receive |
|---|---|---|
| Training sample | All patients over 18 years old with and without with valvular heart disease confirmed by the results of the echocardiography and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA and others). Receives: Diagnostic Test: No intervention (observational study) | |
| Test sample | All patients over 18 years old with and without with valvular heart disease confirmed by the results of the echocardiography and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA and others). Receives: Diagnostic Test: No intervention (observational study) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Parameters of single-channel ECG that have a reliable correlation with the presence of valvular heart defects
comparison of the presence of valvular heart defects detected by the results of an echocardiographic study with the results of the presence of valvular heart defects obtained using the mathematical model of a single-channel ECG monitor
Measured: through study completion, an average of 2 years
Determination of sensitivity of valvular heart defects of multivariate models for analyzing single-channel electrocardiogram data
Comparison of the presence of valvular heart defects detected by the results of an echocardiographic study with the results of the presence of valvular heart defects obtained using the mathematical model of a single-channel ECG monitor
Measured: through study completion, an average of 2 years
Determination of specificity of valvular heart defects of multivariate models for analyzing single-channel electrocardiogram data
Comparison of the presence of valvular heart defects detected by the results of an echocardiographic study with the results of the presence of valvular heart defects obtained using the mathematical model of a single-channel ECG monitor
Measured: through study completion, an average of 2 years
Determination of diagnostic accuracy of valvular heart defects of multivariate models for analyzing single-channel electrocardiogram data
Comparison of the presence of valvular heart defects detected by the results of an echocardiographic study with the results of the presence of valvular heart defects obtained using the mathematical model of a single-channel ECG monitor
Measured: through study completion, an average of 2 years
Secondary outcomes (20)
Significance of the parameter TpTe on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter VAT on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter QTc on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter QT / TQ on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter QRS_E on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter TA on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter TP_E on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter BETA on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter SBETA on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter RonsF on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter RoffsF on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter PpeakP on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter QRS_Ei on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter T_Ei on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter HFQRS on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter PpeakN on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter Tenergy on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter Tpeak on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter Tons on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
significance of the parameter Toffs on the ECG in the determination of valvular heart defects
an ECG spectral analysis will be performed using the Fourier Transform
Measured: through study completion, an average of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2025
- Study start1 Jan 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Valvular Heart Disease Stenosis and RegurgitationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- I.M. Sechenov First Moscow State Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Philipp Kopylov, Prof., Study director, I.M. Sechenov First Moscow State Medical University (Sechenov University)Natalia Kuznetsova, Dr., Principal investigator, I.M. Sechenov First Moscow State Medical University (Sechenov University)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07099417
- Sponsor's protocol ID
- 29-24
- Status last verified
- Jul 2025
- First submitted
- 25 Jul 2025
- Last updated
- 1 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It is not possible to provide documentation due to the prohibition received from the local ethics committee
Publications
Hata E, Seo C, Nakayama M, Iwasaki K, Ohkawauchi T, Ohya J. Classification of Aortic Stenosis Using ECG by Deep Learning and its Analysis Using Grad-CAM. Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:1548-1551. doi: 10.1109/EMBC44109.2020.9175151.
PubMed 33018287Pandey A, Adedinsewo D. The Future of AI-Enhanced ECG Interpretation for Valvular Heart Disease Screening. J Am Coll Cardiol. 2022 Aug 9;80(6):627-630. doi: 10.1016/j.jacc.2022.05.034. No abstract available.
PubMed 35926936